Oncopeptides Balance Sheet Health
Financial Health criteria checks 5/6
Oncopeptides has a total shareholder equity of SEK56.8M and total debt of SEK106.5M, which brings its debt-to-equity ratio to 187.5%. Its total assets and total liabilities are SEK238.4M and SEK181.6M respectively.
Key information
187.5%
Debt to equity ratio
kr106.49m
Debt
Interest coverage ratio | n/a |
Cash | kr173.41m |
Equity | kr56.78m |
Total liabilities | kr181.60m |
Total assets | kr238.38m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 0RN4's short term assets (SEK202.9M) exceed its short term liabilities (SEK44.9M).
Long Term Liabilities: 0RN4's short term assets (SEK202.9M) exceed its long term liabilities (SEK136.7M).
Debt to Equity History and Analysis
Debt Level: 0RN4 has more cash than its total debt.
Reducing Debt: 0RN4's debt to equity ratio has increased from 0% to 187.5% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 0RN4 has sufficient cash runway for 7 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: 0RN4 is forecast to have sufficient cash runway for 9 months based on free cash flow estimates, but has since raised additional capital.